Abstract
Type 2 diabetes is a chronic disease that creates atrophic signatures in the brain, including decreases of total and regional volume of grey matter, white matter, and cortical thickness. However, there is a lack of studies assessing cortical gyrification in type 2 diabetes. Changes in this emerging feature has been associated mainly with genetic legacy, but environmental factors may also play a role. Here, we investigated alterations of the gyrification index and classical morphometric measures in type 2 diabetes, a disease with complex etiology with both underlying genetic and more preponderant environmental factors.
In this cross-sectional study we analyzed brain anatomical magnetic resonance images of 86 participants with type 2 diabetes and 40 healthy control participants, to investigate structural alterations in type 2 diabetes, including whole-brain volumetric measures, local alterations of grey matter volume, cortical thickness and the gyrification index.
We found concordant significant decrements in total and regional grey matter volume, and cortical thickness. Surprisingly, the cortical gyrification index was found to be mainly increased in cortical sensory areas in type 2 diabetes. Moreover, it correlated with features of metabolic control. Our findings challenge the classical neurodevelopmental association of gyrification mostly with genetic determinants. While we found mainly increased gyrification in more genetically constrained sensory areas in type 2 diabetes, our correlation results concurrently suggest an influence of metabolic control in alterations of gyrification in type 2 diabetes. Further studies should address causal influences of genetic and/or environmental factors in patterns of cortical gyrification in type 2 diabetes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Fundacao para a Ciencia e Tecnologia (UID/4959/2020, DSAIPA/DS/0041/2020, DoIT - Diamarker: a consortium for the discovery of novel biomarkers in diabetes - QREN-COMPETE), INFARMED Research Fund for Health (FIS-FIS-2015-01 DIA - DiaMarkData), and the European Foundation for the Study of Diabetes (EFSD) 2019 - Innovative Measurement of Diabetes Outcomes 2019. Fundacao para a Ciencia e Tecnologia also funded an individual grant to JVD (Individual Scientific Employment Stimulus 2017 - CEECIND/00581/2017).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Comissao de Etica da Faculdade de Medicina da Universidade de Coimbra and was conducted in accordance with the declaration of Helsinki. All participants provided written informed consent to participate in the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
